2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
申请人:Neustadt R. Bernard
公开号:US20070066620A1
公开(公告)日:2007-03-22
Compounds having the structural formula I
or a pharmaceutically acceptable salt thereof, wherein
R is R
1
-isoxazolyl, R
1
-oxadiazolyl, R
1
-dihydrofuranyl, R
1
-pyrazolyl, R
1
-imidazolyl, R
1
-pyrazinyl or R
1
-pyrimidinyl;
R
1
is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.
具有结构式I或其药用可接受盐的化合物,其中R是R1-异噁唑基、R1-噁唑啉基、R1-二氢呋喃基、R1-吡唑基、R1-咪唑基、R1-吡啶基或R1-嘧啶基;R1是从H、烷基、烷氧基和卤代中选择的1、2或3个取代基;Z是可选择取代的芳基或可选择取代的杂芳基;公开了这些化合物及其在治疗中枢神经系统疾病,特别是帕金森病和额外锥体综合征中的用途,包括它们的药物组合物和与其他药剂的组合。